RETRACTION: The Long Non-Coding RNA SBF2-AS1 Exerts Oncogenic Functions in Gastric Cancer by Targeting the miR-302b-3p/E2F Transcription Factor 3 Axis (Retraction of Vol 12, Pg 8879, 2019)
ONCOTARGETS AND THERAPY
Authors: Liang, C.; Yue, C.; Liang, C.
Abstract
Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy
PHARMACOGENOMICS
Authors: Chen, Yongzhen; Fang, Fang; Kidwell, Kelley M.; Vangipuram, Kiran; Marcath, Lauren A.; Gersch, Christina L.; Rae, James M.; Hayes, Daniel F.; Smith, Ellen M. Lavoie; Henry, N. Lynn; Beutler, Andreas S.; Hertz, Daniel L.
Abstract
Aim: This study explored whether inherited variants in genes causing the hereditary neuropathy condition Charcot-Marie-Tooth disease are associated with sensitivity to paclitaxel-induced peripheral neuropathy (PN). Patients & methods: Hereditary neuropathy genes previously associated with risk of paclitaxel-induced PN were sequenced in paclitaxel-treated patients. Eight putative genetic predictors in five hereditary neuropathy genes (ARHGEF10, SBF2, FGD4, FZD3 and NXN) were tested for association with PN sensitivity after accounting for systemic exposure and clinical variables. Results: FZD3 rs7833751, a proxy for rs7001034, decreased PN sensitivity (additive model, beta = -0.41; 95% CI: -0.66 to -0.17; p = 0.0011). None of the other genetic predictors were associated with PN sensitivity. Conclusion: Our results support prior evidence that FZD3 rs7001034 is protective of PN and may be useful for individualizing paclitaxel treatment to prevent PN.
COA
Publication 
Loading ......
